Johnson & Johnson (NYSE:JNJ) is First Fiduciary Investment Counsel Inc.’s 10th Largest Position

First Fiduciary Investment Counsel Inc. reduced its stake in Johnson & Johnson (NYSE:JNJ) by 0.3% during the third quarter, according to its most recent filing with the SEC. The fund owned 92,814 shares of the company’s stock after selling 323 shares during the quarter. Johnson & Johnson accounts for approximately 3.0% of First Fiduciary Investment Counsel Inc.’s portfolio, making the stock its 10th largest holding. First Fiduciary Investment Counsel Inc.’s holdings in Johnson & Johnson were worth $15,041,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in the stock. Holistic Planning LLC grew its holdings in Johnson & Johnson by 39.4% during the third quarter. Holistic Planning LLC now owns 2,995 shares of the company’s stock valued at $485,000 after purchasing an additional 847 shares during the period. CWA Asset Management Group LLC bought a new position in shares of Johnson & Johnson during the 3rd quarter worth $21,927,000. Equitable Trust Co. increased its holdings in Johnson & Johnson by 12.2% in the 3rd quarter. Equitable Trust Co. now owns 56,743 shares of the company’s stock worth $9,196,000 after acquiring an additional 6,166 shares during the last quarter. Source Financial Advisors LLC raised its stake in Johnson & Johnson by 7.8% in the 3rd quarter. Source Financial Advisors LLC now owns 2,298 shares of the company’s stock valued at $372,000 after acquiring an additional 166 shares during the period. Finally, Leavell Investment Management Inc. boosted its position in Johnson & Johnson by 3.4% during the third quarter. Leavell Investment Management Inc. now owns 39,507 shares of the company’s stock worth $6,403,000 after purchasing an additional 1,289 shares during the period. Institutional investors own 69.55% of the company’s stock.

Analyst Upgrades and Downgrades

JNJ has been the topic of several research reports. Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a research report on Wednesday, October 16th. Wells Fargo & Company boosted their target price on shares of Johnson & Johnson from $163.00 to $166.00 and gave the company an “equal weight” rating in a report on Wednesday, October 16th. Royal Bank of Canada raised their price target on Johnson & Johnson from $178.00 to $181.00 and gave the stock an “outperform” rating in a report on Wednesday, October 16th. Sanford C. Bernstein boosted their price objective on Johnson & Johnson from $161.00 to $171.00 in a research note on Thursday, July 18th. Finally, StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, September 14th. Seven analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $175.00.

Johnson & Johnson Stock Performance

NYSE JNJ opened at $155.47 on Friday. The company has a market capitalization of $374.31 billion, a P/E ratio of 22.50, a P/E/G ratio of 2.80 and a beta of 0.53. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03. Johnson & Johnson has a 52-week low of $143.13 and a 52-week high of $168.85. The company has a fifty day moving average of $162.61 and a 200-day moving average of $155.81.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.21 by $0.21. The firm had revenue of $22.47 billion during the quarter, compared to analysts’ expectations of $22.17 billion. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The company’s revenue for the quarter was up 5.2% compared to the same quarter last year. During the same period in the prior year, the business earned $2.66 EPS. As a group, equities research analysts predict that Johnson & Johnson will post 9.94 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be paid a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a dividend yield of 3.19%. The ex-dividend date of this dividend is Tuesday, November 26th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 71.78%.

Insider Transactions at Johnson & Johnson

In related news, VP Robert J. Decker sold 5,635 shares of the stock in a transaction on Friday, August 30th. The shares were sold at an average price of $165.06, for a total transaction of $930,113.10. Following the transaction, the vice president now owns 18,973 shares of the company’s stock, valued at approximately $3,131,683.38. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.